Article Versions Notes

Rybinska I, Sandri M, Bianchi F, Orlandi R, De Cecco L, Gasparini P, Campiglio M, Paolini B, Sfondrini L, Tagliabue E, et al. Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment. Cells. 2020; 9(2):434. https://doi.org/10.3390/cells9020434

Rybinska, Ilona, Marco Sandri, Francesca Bianchi, Rosaria Orlandi, Loris De Cecco, Patrizia Gasparini, Manuela Campiglio, Biagio Paolini, Lucia Sfondrini, Elda Tagliabue, and et al. 2020. "Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment" Cells 9, no. 2: 434. https://doi.org/10.3390/cells9020434

Rybinska, I., Sandri, M., Bianchi, F., Orlandi, R., De Cecco, L., Gasparini, P., Campiglio, M., Paolini, B., Sfondrini, L., Tagliabue, E., & Triulzi, T. (2020). Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment. Cells, 9(2), 434. https://doi.org/10.3390/cells9020434